RT Journal Article
SR Electronic
T1 Post-acute sequelae of SARS-CoV-2 (PASC) impact quality of life at 6, 12 and 18 months post-infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.08.22278543
DO 10.1101/2022.08.08.22278543
A1 Demko, Zoe O
A1 Yu, Tong
A1 Mullapudi, Sarika K.
A1 Varela Heslin, M. Gabriela
A1 Dorsey, Chamia A.
A1 Payton, Christine B.
A1 Tornheim, Jeffrey A.
A1 Blair, Paul W.
A1 Mehta, Shruti H.
A1 Thomas, David L.
A1 Manabe, Yukari C.
A1 Antar, Annukka A.R.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/08/09/2022.08.08.22278543.abstract
AB Little data exist on long COVID outcomes beyond one year. In a cohort enrolled with mild-moderate acute COVID-19, a wide range of symptoms manifest at 6, 12, and 18 months. Endorsing over 3 symptoms associates with poorer quality of life in 5 domains: physical, social, fatigue, pain, and general health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Henry M. Jackson Foundation for the Advancement of Military Medicine [1007957 to P.W.B. and Y.C.M.]; the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program [to P.W.B. and Y.C.M.]; and the National Institute of Allergy and Infectious Diseases (K08AI143391 to A.A.R.A., K23AI135102 to J.A.T.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Johns Hopkins Medicine gave ethical approval for this work (IRB00259948).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.